Formation and Investigation of Cell‐Derived Nanovesicles as Potential Therapeutics against Chronic Liver Disease
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Aymar Abel Ganguin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, 3012, Switzerland. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A new therapeutic approach using cell‐derived nanovesicles (cdNVs) is offered here to overcome the lack of effective treatments for liver fibrosis, a reversible chronic liver disease. To achieve this goal the formation and purification of cdNVs from untreated, quiescent‐like, or activated LX‐2 cells, an immortalized human hepatic stellate cell (HSC) line with key features of transdifferentiated HSCs are established. Analysis of the genotype and phenotype of naïve and transdifferentiated LX‐2 cells activated through transforming growth factor beta 1, following treatment with cdNVs, reveals a concentration‐dependent fibrosis regression. The beneficial fibrosis‐resolving effects of cdNVs are linked to their biomolecular corona. Liposomes generated using lipids extracted from cdNVs exhibit a reduced antifibrotic response in perpetuated LX‐2 cells and show a reduced cellular uptake. However, incubation with soluble factors collected during purification results in a new corona, thereby restoring fibrosis regression activity. Overall, cdNVs display encouraging therapeutic properties, making them a promising candidate for the development of liver fibrosis resolving therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, 3012, Switzerland.
- Functional Genomics Center Zurich (FGCZ), University of Zurich/ETH Zurich, Zurich, 8057, Switzerland.
ORCID-Profile: Aymar Abel Ganguin, Ivo Skorup, Sebastian Streb, Alaa Othman, Paola Luciani
Zitieren
APA
Ganguin, A. A., Skorup, I., Streb, S., Othman, A., & Luciani, P. (2023). Formation and Investigation of Cell‐Derived Nanovesicles as Potential Therapeutics against Chronic Liver Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300811
Vancouver
Ganguin AA, Skorup I, Streb S, Othman A, Luciani P. Formation and Investigation of Cell‐Derived Nanovesicles as Potential Therapeutics against Chronic Liver Disease. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300811
BibTeX
@article{Ganguin2023,
author = {Ganguin, Aymar Abel and Skorup, Ivo and Streb, Sebastian and Othman, Alaa and Luciani, Paola},
title = {Formation and Investigation of Cell‐Derived Nanovesicles as Potential Therapeutics against Chronic Liver Disease},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300811}
}
EUVIMED